RSPH10B2

Across TCGA pan-cancer cohorts, RSPH10B2 Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated RSPH10B2 data layer compared with 25 for mass-spec protein.

The strongest signal is observed in skin cutaneous melanoma (SKCM), where higher RSPH10B2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated RSPH10B2 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

SKCM, OV, and UCEC are the cancer types where RSPH10B2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SKCM	DFS	Median	All	0.203	0.623	.001	20	view →
OV	OS	Median	II,III,IV	0.323	0.843	.001	18	view →
UCEC	DFS	Median	All	1.000	0.628	.017	14	view →
MESO	DFS	Median	III,IV	0.078	0.376	.012	9	view →
ESCA	OS	Median	II,III,IV	0.216	0.702	.014	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
READ	OS	Median	All	0.281	0.830	.006	3	view →
LUAD	OS	Median	All	0.312	0.673	.048	3	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

RSPH10B2–SKCM (DFS)

Open the SKCM breakdown →